Findings from this and other related studies could provide impetus to further establish use of anti-VEGFR2 and other potential anti-VEGF agents [19-21] as therapeutic interventions for treatment and prevention of vascular leakage associated with DHF. This evidence concerns the gene VEGFA and Dengue hemorrhagic fever.